Health Trials

Metastatic Biliary Tract Cancer

3

Review clinical trials related to Metastatic Biliary Tract Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

To evaluate combination therapy of adding CTX-009 to the standard therapy GCD as first-line therapy in patients with unresectable or mBTC.

Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jul 16, 2026Locations: 1
Eligibility criteria

Age ≥ 18 years. Because no dosing or adverse event data are currently available... [+25]

Previous treatment of the current malignancy. Patients who received prior periop... [+28]

Read more
Status: Recruiting

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Based on preclinical data from the Lim lab (WUSM), the investigators hypothesize that IRAK4 inhibition cripples tumor-intrinsic survival signaling and effectively overcomes the desmoplastic and immune-suppressive tumor microenvironment (TME) to render chemo- and immunotherapies effective in GI malignancy. Therefore, this trial is designed to evaluate the combination of emavusertib (CA-4948) and standard chemoimmunotherapy in untreated advanced or metastatic biliary tract cancer (BTC).

Participants needed: 48
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Washington University School of MedicineUpdated: Apr 3, 2026Locations: 1
Eligibility criteria

Advanced unresectable or metastatic histologically or cytologically confirmed ad... [+16]

Current use or anticipated need for alternative, holistic, naturopathic, or bota... [+19]

Read more
Status: Not yet recruiting

Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer

To evaluate the efficacy and safety of inetetamab in combination with chemotherapy ± immunotherapy as a first-line treatment for HER2-positive advanced biliary tract cancer, providing theoretical evidence and practical guidance for further optimizing treatment regimens and improving therapeutic outcomes.

Participants needed: 35
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Eastern Hepatobiliary Surgery HospitalUpdated: Feb 10, 2025
Eligibility criteria

Males or females aged ≥18 years; [+9]

Known allergy or contraindication to any component of the study drugs; [+13]

Read more